Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 29, 2022 at 10:25 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 181.4 million compared to CNY 120.87 million a year ago. Revenue was CNY 181.4 million compared to CNY 120.87 million a year ago. Net income was CNY 3.34 million compared to CNY 27.55 million a year ago. Basic earnings per share from continuing operations was CNY 0.0038 compared to CNY 0.0313 a year ago. Diluted earnings per share from continuing operations was CNY 0.0038 compared to CNY 0.0313 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.